- This event has passed.
Antimicrobial Drugs Advisory Committee (AMDAC) Meeting
November 30 @ 9:00 am - 5:00 pm EST
The FDA Antimicrobial Drugs Advisory Committee (AMDAC) will convene on 30 November 2021 to discuss Merck and Ridgeback’s request for emergency use (EUA) of molnupiravir oral capsules for treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. an investigational antiviral drug to treat COVID-19.
FDA intends to make background material available to the public no later than two (2) business days before the meeting.
Background material and the link to the online teleconference meeting room will be available at 2021 Meeting Materials, Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee.
Public Participation Information
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2021-N-0758. The docket will close on November 29, 2021. Submit either electronic or written comments on this public meeting by November 29, 2021.
Comments received on or before November 15, 2021, will be provided to the committee(s). Comments received after that date but by November 29, 2021, will be taken into consideration by FDA.
Learn more at the FDA meeting announcement website.